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Clostridium difficile infection (CDI) is the most common healthcare associated infection and
is highly prevalent in Europe and North America. Limited data is available on the prevalence
of CDI in Asia. However, secular increases in prevalence of risk factors for CDI suggest that
it may be emerging as a major cause of morbidity, highlighting the urgent need for a system-
atic study of the prevalence of CDI in Asia.
Methods
We systematically searched PubMed/Medline and Embase for publications from Asia
between 2000–16 examining prevalence of CDI. A random-effects meta-analysis was per-
formed to calculate the pooled prevalence of CDI in Asia and to identify subgroups and
regions at high risk.
Results
Our meta-analysis included 51 studies from throughout Asia including 37,663 patients at risk
among whom confirmed CDI was found in 4,343 patients. The pooled proportion of confirmed
CDI among all patients with diarrhea was 14.8% with a higher prevalence in East Asia (19.5%),
compared with South Asia (10.5%) or the Middle East (11.1%). There were an estimated 5.3
episodes of CDI per 10,000 patient days, similar to rates reported from Europe and North
America. Infections due to hypervirulent strains were rare. CDI-related mortality was 8.9%.
Conclusions
In a meta-analysis of 51 studies, we observed similar rates of CDI in Asia in comparison to
Europe and North America. Increased awareness and improved surveillance of Clostridium
difficile is essential to reduce incidence and morbidity.







Citation: Borren NZ, Ghadermarzi S, Hutfless S,
Ananthakrishnan AN (2017) The emergence of
Clostridium difficile infection in Asia: A systematic
review and meta-analysis of incidence and impact.
PLoS ONE 12(5): e0176797. https://doi.org/
10.1371/journal.pone.0176797
Editor: Abhishek Deshpande, Cleveland Clinic,
UNITED STATES
Received: January 17, 2017
Accepted: April 17, 2017
Published: May 2, 2017
Copyright: © 2017 Borren et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: The minimal dataset
is within the Supporting Information file.
Funding: Ananthakrishnan has served on the
scientific advisory boards for Cubist
pharmaceuticals and Merck and has received
research funding from Merck. The funders had no
role in study design, data collection and analysis,
decision to publish, or preparation of the
manuscript.
Competing interests: Ananthakrishnan has served
on the scientific advisory boards for Cubist
Introduction
Clostridium difficile infection (CDI) is the most common healthcare associated infection
(HAI). Since its identification as the cause of pseudomembranous colitis in 1978[1], it has
emerged as an important cause of morbidity particularly among hospitalized patients and led
to epidemics with high mortality. An estimated 453,000 infections occur annually in the
United States, 172,000 in Europe, and 18,005 in England.[2–4] Recognition of the burden of
CDI has led to a multi-pronged strategy of provider education, institution of systematic test-
ing, antibiotic stewardship and infection control programs which has blunted the rise, and
even reduced the incidence of this infection in North America and Europe.[5, 6]
In contrast, little is known about the prevalence and impact of CDI in Asia as few systematic
studies exist and testing remains infrequent, hampered by both a low index of clinical suspi-
cion and the lack of readily available laboratory testing.[7] Yet, several factors favor the possi-
ble emergence of C. difficile as an important pathogen in Asia.[8, 9] While traditionally
considered home to a young population, with improved life expectancy and control of other
infectious diseases, many countries in Asia are witnessing an aging of their demographics and
in most studies, the elderly are particularly susceptible to CDI.[10, 11] Chronic diseases, also a
risk factor for CDI, have increased in prevalence, and so has the need for frequent healthcare
contact and hospitalizations. In addition, antibiotic use, the strongest risk factor for CDI, is
often indiscriminate and unregulated in some Asian countries.[12, 13]
Thus, there is an important need for systematic study of the prevalence and impact of CDI
in Asia to inform both clinical practice as well as healthcare policy. We performed this system-
atic review and meta-analysis to (1) quantify the burden of CDI among countries in Asia; (2)
identify subgroups and regions at high risk within this population; and (3) define the propor-
tion of hypervirulent epidemic strains of C. difficile; and (4) quantify CDI-related mortality in
comparisons to studies from the west.
Methods
Literature search
We conducted a systematic search of the MEDLINE/PubMed and EMBASE databases for
studies providing prevalence or incidence rates of CDI in Asia. To quantify current burden,
our search was limited to publications from January 2000 to June 2016. No language restric-
tions were applied in our search, but inclusion of the study in our full analysis required at least
the abstract to be available in English. Our search strategy combined 3 different phrase groups
by using the Boolean operator “AND” (S1 Table). The first search group consisted of terms rel-
evant to identify CDI and included combination of “Clostridium difficile”, “C difficile” and “C
diff” and “Pseudomembranous colitis”. The second group defining location included both
broadly the phrase “Asia” as well as specific countries within Asia including China, Hong
Kong, India, Iran, Israel, Japan, Korea, Malaysia, Singapore, Taiwan, Thailand and Turkey.
The final search terms defined the outcome of interest and included “prevalence”, “incidence”,
“epidemiology”, and “frequency”. The citation list from all eligible studies and reviews were
also perused to identify other relevant studies.
Inclusion and exclusion criteria
Studies were eligible for inclusion if they provided information on the incidence of CDI in
Asia reported either as proportion of tests positive for toxigenic C. difficile among symptomatic
patients testing, per 1000 hospital discharges, or per 10,000 patient days. Studies examining C.
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difficile carriage among asymptomatic individuals were excluded. Eligible studies could
include either an inpatient or outpatient population.
Data collection
The decision for inclusion of each study was made by two authors (NZB and ANA) who inde-
pendently screened the studies by title and abstract. The following data were extracted from
each study: year of publication, location, setting (inpatient or outpatient), population (nosoco-
mial diarrhea, antibiotic-associated diarrhea, other), number of patients tested, and number of
patients with confirmed CDI. The microbiological method for diagnosis of CDI was noted and
where available, the results of molecular characterization for specific ribotypes. From each
study, mean age prevalence of risk factors for CDI including exposure to antibiotics, use of
proton pump inhibitors (PPI), and recent hospitalization were noted. Studies were grouped
into three geographic regions: South Asia (India, Malaysia, Pakistan, Singapore, and Thailand),
East Asia (China, Hong Kong, Japan, Korea, Taiwan) and the Middle East (Iran, Jordan,
Kuwait, Lebanon, Qatar, Turkey). When necessary, attempts were made to contact the corre-
sponding authors for additional pertinent information.
Outcomes
The primary outcome of interest was expressed in one of three ways: (1) the proportion of
tests positive for toxigenic C. difficile from among all patients with diarrhea; (2) rate of CDI per
1,000 admissions; and (3) the rate of CDI per 10,000 patient days. Our secondary outcome was
CDI-associated mortality.
Assessment of study quality
We used the Newcastle-Ottawa Quality Assessment Scale (NOS) to assess study quality. This
scale ranks studies in 3 groups based on the selection of the cohort; the comparability of the
cohorts; and the completeness of ascertainment of the outcome. Each study could receive up
to 4 stars. Studies were considered representative if they consisted of an unselected group of
patients and did not focus on individuals with specific comorbidities alone. Ascertainment
bias was considered to be absent if all patients with diarrhea underwent similar testing strate-
gies; reliance on clinical suspicion to trigger testing for select patients was deemed susceptible
to bias.
Statistical analysis
Heterogeneity between the studies was determined using the Cochran’s Q and I2 statistics.
An I2 > 50% or p< 0.10 indicated significant heterogeneity. A DerSimonian and Laird ran-
dom effects model was used for all analyses to determine the pooled prevalence rates (and 95%
confidence intervals (CI)) for proportion of stool tests that were positive for C. difficile as well
as rates per 1,000 admissions and 10,000 patient days. Pre-specified subgroup analysis was per-
formed stratifying by setting, geographic region, and population under study (antibiotic-asso-
ciated diarrhea, all nosocomial diarrhea). Publication bias was examined using the Egger test
and visual examination of the funnel plot. Sources of heterogeneity between studies were iden-
tified by performing a meta-regression. All data were recorded in a Microsoft Excel spread-
sheet (Microsoft Corp, Redmond, WA) and statistical analysis carried out using Stata 13.2
(StataCorp, College Station, TX).
C. difficile infection in Asia
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Results
Literature search
Our search of MEDLINE/Pubmed yielded 448 citations. Of these, 393 citations were excluded
on initial screening of the title and abstract and the full text of remaining 55 articles were
reviewed (Fig 1). Two articles representing duplicate data[14, 15], 2 with insufficient informa-
tion[16, 17], and 4 examining C. difficile carriage in healthy individuals were excluded[18–21],
resulting in a final cohort of 48 unique studies.[9, 22–71] Of these, only the abstract was avail-
able for review in English in 7 studies but sufficient relevant information could be extracted to
allow for inclusion.[60–66, 71] A search on Embase yielded 3 additional studies that were eligi-
ble for inclusion. One large study from Thailand was not included as it did not include micro-
biological confirmation of CDI.[72]
Study characteristics
The characteristics of the included studies are summarized in Table 1. Forty two included only
hospitalized patients[9, 22–24, 28–40, 42, 43, 46, 48, 50–55, 57, 59–67, 69–71], 1 was exclu-
sively among outpatients[47], and 8 included both groups.[25, 26, 41, 44, 45, 49, 56, 68] A total
of 16 countries were represented, with China contributing the largest number of studies.
Twenty-five studies were from East Asia[9, 22, 24, 26, 28, 34–37, 39–42, 44, 52–54, 56, 58–61,
67, 70, 71], 16 from South Asia[23, 25, 27, 29, 31, 33, 43, 46, 51, 55, 62–64, 66, 68, 69] and 10
from the Middle East.[30, 32, 38, 45, 47–50, 57, 65] The mean age of included patients was 60
years (data from 24 studies) and just fewer than half the cohort were women (43%, 34 studies).
From 28 studies presenting data on antibiotic use; a mean of 84% of patients had been exposed
recently (range 26–100%). Sixteen studies examining PPI use yielded a mean proportion of
49% (range 5–90%). From twenty-one studies where this data was available, the pooled pro-
portion of recent hospitalization was 71% (range 19–100%).
The included studies varied in the testing modality to determine CDI. The most commonly
performed tests were anaerobic or toxigenic culture (71%) and the enzyme immunoassay
(EIA) (52%). Nearly half the studies also reported using polymerase chain reaction / nucleic
acid amplification test (PCR-NAAT) (51%). Other diagnostic tests used were cell culture cyto-
toxicity neutralization assay (CCNA) (8%), glutamate dehydrogenase assay (GDH) (6%), and
lower gastrointestinal endoscopy (11%). Molecular characterization of C. difficile ribotype was
Fig 1. Flowchart of the literature search.
https://doi.org/10.1371/journal.pone.0176797.g001
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Table 1. Characteristics of included studies.
Publication
year
Author Region Setting Study
population
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performed in one-third of the included studies (n = 15). The mean proportion of infections
due to ribotype 027 was 0.3% (range 0–2.1%) and from 12 studies, the proportion of ribotype
017 was 14% (range 0–48%).
Proportion of C. difficile positivity
This pooled analysis included 37,663 patients tested among whom CDI was confirmed in
4,343 patients. The overall pooled C. difficile positive rate was 14.8% (95% CI 12.9–16.7%) (Fig
2). However, there was significant heterogeneity between the studies (I2 = 96.3%, p<0.001),
with rates from individual studies ranging from 2.0% to 61.4%. The pooled proportion of CDI
was greater in the 37 studies restricted to hospitalized patients (16.4%, 95% CI 14.1–18.7%)
than those with a mixed inpatient-outpatient population (11.1%, 95% CI 7.9–14.4%). The sin-
gle study examining outpatients alone reported a significantly lower prevalence of 5.3%
(p< 0.001)[47]. The prevalence of CDI was greater among studies restricting testing to antibi-
otic-associated diarrhea (25 studies, 20.9%) compared to all hospitalized patients with diarrhea
(33 studies, 13.5%; p< 0.001).
There was significant regional variation in occurrence of CDI. The proportion of C. difficile
positivity was significantly higher among studies from East Asia (19.5%, 95% CI 15.5–23.5%,
21 studies) compared to those from the Middle East (11.1%, 95% CI 7.8–14.4%, 9 studies) or
South Asia (10.5%, 95% CI 7.9–13.1%, 16 studies) (p< 0.001) (Fig 3, S1 Fig).
Rates of C. difficile infection among hospitalized patients
Eighteen studies provided extractable data on incidence per 1,000 admissions, yielding a
pooled rate of 3.2 cases of CDI per 1,000 admissions (95% CI 2.4–3.9). However there was sig-
nificant heterogeneity between the studies (I2 = 99.3%). Eleven studies provided sufficient
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pooled incidence of CDI of 5.3 per 10,000 patient-days (95% CI 4.0–6.7) (Fig 4). Excluding
one study conducted exclusively in a high risk ICU population did not significantly alter the
pooled incidence (4.9 per 10,000 patient days).[36]
Outcomes of CDI
Thirteen studies provided information on CDI-related mortality (range 30–180
days).22,24,28,36,41,44,45,49,57–60,62 The random effects pooled rate of CDI-related death was 8.9%
(95% CI 5.4%– 12.3%).
Meta-regression
As most studies reported proportion of C. difficile positive tests as their outcome, meta-regres-
sion to identify influential covariates were performed for this outcome. Only geographic
region of origin achieved statistical significance while there was a trend towards significance
for the proportion of patients recently (S2 Table). Study setting, number of included patients,
year of study, and proportion of patients exposed to antibiotics or PPI were not associated
with rate of CDI. Specifically, we also did not identify a temporal trend over time in the pro-
portion of stool tests that were positive for C. difficile (S2 Fig).
Study quality and publication bias
S3 Table presents the quality scores for the included studies. While not all fields of the NOS
were applicable for our meta-analysis, all studies were deemed of adequate quality to be
included in the analysis. Begg and Egger tests both showed significant likelihood of publication
bias (p = 0.046 and p<0.001, respectively) (S3 Fig).
Fig 2. Forest plot of proportion of C. difficile positive tests among all patients tested.
https://doi.org/10.1371/journal.pone.0176797.g002
C. difficile infection in Asia
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Discussion
The contribution of CDI to morbidity and mortality among hospitalized patients is well recog-
nized in North America and Europe. However, little is known about whether C. difficile is
Fig 3. Forest plot of proportion of C. difficile positive tests among all patients tested, by region.
https://doi.org/10.1371/journal.pone.0176797.g003
Fig 4. Forest plot of incidence rate of C. difficile infection per 10,000 patient days among hospitalized
patients.
https://doi.org/10.1371/journal.pone.0176797.g004
C. difficile infection in Asia
PLOS ONE | https://doi.org/10.1371/journal.pone.0176797 May 2, 2017 9 / 16
equally prevalent and consequential in Asia. A systematic study of this is important to not only
accurately quantify the burden of CDI in a population witnessing an increase in many of its
risk factors, but also essential to inform disease surveillance and interventions to prevent the
dramatic rise in incidence noted elsewhere.
Our systematic review demonstrated a pooled prevalence of CDI of 14.8% among all
patients tested and 16.4% among hospitalized patients with diarrhea. These findings are simi-
lar to the estimates from other regions. In a multi-country European surveillance study, the
proportion of stool samples positive for C. difficile ranged from 4 to 39%[73]. A multicenter
study by the Centers for Disease Control (CDC) in the United States performing surveillance
for C. difficile revealed a similar rate of positive tests, ranging from 7% to 20%.[74] In a nation-
wide study from Spain analyzing 807 stool specimens, 7.8% were found to be positive for C.
difficile.[75]
The pooled incidence rate of CDI from Asia in our meta-analysis was 5.3 per 10,000 patient
days. This is similar to reports from western countries. In a multicenter study from Europe,
the incidence of CDI was reported as 4.1 per 10,000 patient days.[73] In the EUCLID study,
the mean incidence rate was similarly 7 per 10,000 patient days with estimates from individual
countries varying from 0.7 to 28.7.[76] A nationwide systematic study from Spain placed the
rate at 3.8 per 10,000 patient-days.[75] The incidence is similar in the United States with a
median hospital-onset CDI rate of 5.4 per 10,000 patient days.[77] As well, the pooled CDI-
related mortality rate of 8.9% is also comparable to western estimates; for example, Lessa et al.
reported a mortality rate of 6.4% in a systematic study from the United States.[78] Thus,
despite the perception of CDI being uncommon in Asia, our findings suggest that the inci-
dence and impact is similar to that noted in the West.
Among studies were molecular characterization of CDI was performed, the prevalence of
hypervirulent ribotype 027 was only 0.3%. In comparison, this ribotype accounted for 21% of
all C. difficile isolates[79] in the CDRN and 19% in the European EUCLID study.[76] While lit-
erature is not uniformly consistent on the impact of this strain, it has been associated with
higher levels of toxin production and hypervirulence, [80, 81] leading to outbreaks initially in
Canada and subsequently.[81] While the low prevalence among isolates in Asia is reassuring,
the high rates of fluoroquinolone use in this population and the resistance of the ribotype 027
strain to this antibiotic class makes it essential to conduct regular surveillance for this strain.
[13, 82]
There are several implications to our findings. Despite the recognition of CDI as an impor-
tant HAI, there remains the perception of it being infrequent or inconsequential in Asia. In
contrast to this, our results demonstrate both an incidence and mortality comparable to the
west. Two narrative reviews, by Collins et al.[8] and Burke et al.[83] similarly emphasized the
lack of awareness of CDI among physicians, that, along with our findings here, highlight the
urgent need for education of healthcare professionals in Asia about its burden and impact.
There is the need for appropriate infection control methods within hospitals including hand
washing, contact isolation, minimization of unnecessary and over the counter dispensation of
antibiotics, and development of antibiotic stewardship programs to reduce risk of CDI and
prevent emergence of epidemic strains. The need for such measures attains additional urgency
as several epidemiologic trends including aging of the population and growing burden of
chronic disease favor escalation of CDI in Asia.
We readily acknowledge several limitations to evidence base contributing to our study.
First, there was significant heterogeneity between the studies. However, a similar wide varia-
tion in incidence has also been observed across hospitals and between countries in the West.
The heterogeneity was not completely explained by region, period of study, sample size, or
testing strategy suggesting that either true variability in prevalence of CDI or the effect of other
C. difficile infection in Asia
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unmeasured factors. Second, nearly all the studies were conducted in a hospitalized setting
and most did not differentiate community acquired from hospital acquired infection. As com-
munity acquired CDI may contribute to up to one-third of all CDI[84, 85], there is a need to
systematically examine its occurrence globally. Only a few studies performed molecular char-
acterization; there is the need for more robust data to accurately define the prevailing strains
in Asia. Fourth, we observed evidence of publication bias and few studies reported on the
impact of CDI on mortality or need for surgery. Finally, we searched the two most widely used
medical literature databases—Embase and Pubmed—for relevant studies. However, we
acknowledge that studies published solely in a regional language in Asia, particularly in smaller
non-indexed journals, may not be comprehensively captured by these databases.
In conclusion, in this systematic review, we document that the burden of CDI in Asia is
similar to that identified in North America and Europe. This highlights the need not only for
further examination of the impact of C. difficile in this understudied geographic region but
also the urgent need to educate providers about its consequence. There is also an important
need for institution of appropriate measures to reduce the risk for development and transmis-
sion of this infection to reduce its adverse impact on patient outcomes.
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